Investigators also glance to assess linvoseltamab in relapsed/refractory many myeloma as Portion of the section 3 LINKER-MM3 trial. Experimental: Dose expansion_sub-populace 2_higher dose of niraparib MTDs and/or candidate RP2Ds for elimusertib applied together with niraparib at a better mounted dose. A complete of 143 patients had been enrolled to the https://beckettszdjn.estate-blog.com/26459608/the-2-minute-rule-for-lx-2931